FDA faces backlog as its workers return; Novo gets Canadian approval for Levemir pen;

@FiercePharma: Biggest story this a.m. online: Pharma dealmakers, listen up; Ireland may close a popular tax loophole. Story | Follow @FiercePharma

@EricPFierce: Another gut check for Amarin and its fish oil drug . F panel votes against wider use. Article | Follow @EricPFierce

@CarlyHFierce: Q3 earnings: Abbott ups dividend, Actelion confirms growth, Baxter hurt by merger costs. More | Follow @CarlyHFierce

> The FDA faces backlog as furloughed workers hit their computers and desks. Story

> Pfizer ($PFE) will be able to expand the product summary for its pneumococcal conjugate vaccine (PCV) Prevenar 13 in Europe to include some expanded groups. Report

> Novo Nordisk ($NVO) says Health Canada has approved is disposable prefilled insulin pen containing the insulin Levemir. Release

> Health activists continue to push South Africa for upgrades to its patent laws to make generics more available. Story

> A new study says that regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) has significant connection with active Crohn's disease, but not with ulcerative colitis. Report

Medical Device News

@FierceMedDev:  buying implant outfit for $80M with eye on Europe. ICYMI yesterday | Follow @FierceMedDev

@MarkHFierce: Roche is closing down its 454 Life Sciences gene sequencing division. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: FierceMedicalDevices' 2013 Fierce 15. Special report | Follow @MichaelGFierce

> LabCorp grew revenue despite Dx reimbursement challenges. Item

> Fierce 15 winner Veracyte discloses IPO details and boosts maximum offering. Story

> Med tech VC spending grew in Q3, but deal numbers declined. Report

> Boston Scientific paying $30M to settle Guidant claims. More

Biotech News

@FierceBiotech: VC funding follows tepid pace in Q3 as first-time rounds shrivel. Special report | Follow @FierceBiotech

@JohnCFierce: Seamus Fernandez is downgrading Sanofi. Likes PCSK9 but thinks prospects are overblown. Lotso competition coming. Very sensible assessment. | Follow @JohnCFierce

@DamianFierce: The third time is not whatsoever charming as Alimera, pSivida get another FDA rejection for Iluvien. Article | Follow @DamianFierce

@EmilyMFierce: Mini pancreas grown in lab using mouse cells. Story from FierceBiotech Research | Follow @EmilyMFierce

> Boehringer snags EU nods for COPD drug as FDA awaits. More

> Bullish Relypsa eyes $138M in bumped-up IPO pitch. Story

> Blood clots force Ariad to shutter PhIII Iclusig trial. Article

And Finally... Researchers have found that generic drugs, on average, capture 60% of the market within 90 days or less. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.